IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	Based on PCT/JP2003/014101	Art Unit:	tba
Filed:	Intl. Filing 05 NOVEMBER 2003	Examiner:	tba
1st Inventor:	Masahiro KAJINO	Allowed:	
For:	Receptor Regulator	Batch:	
Atty. Dkt. No.	3116 US0P	Paper No.:	

Information Disclosure Statement

MAIL STOP PCT
P.O. Box 1450
Commissioner for Patents
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, Applicants request consideration of the references listed on the attached Forms PTO/SB/08A and PTO/SB/08B. A legible copy of each listed reference is herewith being provided to the Examiner.

This Information Disclosure Statement is being submitted within 3 months of the filing date of the above-identified application, and before the mailing date of the first Office Action on the merits, thus, no certification or fee is required.

Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached form PTO/SB/08A be returned in accordance with MPEP §609.

Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call Applicants' attorney.

Respectfully submitted,

Dated: 4/8/05

(847) 383-3372
(847) 383-3391

Mark Chao, Ph.D., Reg. No. 37,293
Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
475 Half Day Road
Lincolnshire, IL 60069 USA

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	Based on PCT/JP03/14101
Filing Date	Intl. Filing 05 NOV 2003
First Named Inventor	Masahiro KAJINO
Art Unit	tba
Examiner Name	tba
Attorney Docket Number	3116 US0P

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US- 4,126,689	11/21/1978	Stefan Sanczuk, et al.	
	A2	US- 4,791,120	12/13/1988	Bor-Sheng Lin, et al	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	A3	WO 01/44297 A1	06/21/2001	Synaptic Pharmaceutical		
	A4	EP 1255109 A1	11/06/2002	Takeda Chemical Industries		
	A5	WO 00/02919	01/20/2000	Merck & Co., Inc.		
	A6	EP 1237001 A1	09/04/2002	Takeda Chemical Industries		
	A7	JP 01-213279 - Abstract	08/28/1989	BOC Group, Inc.		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	Based on PCT/JP03/14101
Filing Date	Intl. Filing 05 NOV 2003
First Named Inventor	Masahiro KAJINO
Art Unit	tba
Examiner Name	tba
Attorney Docket Number	3116 US0P

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	A8	L.V. KUDZMA, et al., "4-Phenyl- and 4-Heteroaryl-4-anilidopiperidines. A Novel Class of Analgesic and Anesthetic Agents", J. Med. Chem., (1989, pp. 2534-2542, Vol. 32.	
	A9	N. SAKURA, et al., "Structure--Activity Relationships of Neuromedin U. IV. Absolute Requirement of the Arginine Residue at Position 7 of Dog Neuromedin U-8 for Contractile Activity", Chem. Pharm. Bull., (2000), pp. 1166-1170, Vol. 48, No. 8.	
	A10	M.J. COLEMAN, et al., "A Convenient Method for the N-Acylation and Esterification of Hindered Amino Acids: Synthesis of Ultra Short Acting Opiod Agonist, Remifentanil", Synlett, (1999), pp. 1923-1224, No. 12.	
	A11	N. MINAMINO, et al., "Neuromedin U-8 and U-25: Novel Uterus Stimulating and Hypertensive Peptides Identified in Porcine Spinal Cord", Biochemical and Biophysical Research Communications, (1985), pp. 1078-1085, Vol. 130, No. 3.	
	A12	L.K. MALENOWICZ, et al., "Effects of Neuromedin U-8 on the Rat Pituitary-Adrenocortical Axis", in vivo, (1993), pp. 419-422, Vol. 7.	
	A13	D.R. Brown, et al., "Neuromedin U Octapeptide Alters Ion Transport in Porcine Jejunum", European Journal of Pharmacology, (1988), pp. 159-162, Vol. 155.	
	A14	S. SUMI, et al., "Effect of Synthetic Neuromedin U-8 and U-25, Novel Peptides Identified in Porine Spinal Cord, on Splanchnic Circulation in Dogs", Life Sciences, (1987), pp. 1585-1590, Vol. 41.	
	A15	C.P. TAN, et al., "Cloning and Characterization of a Human and Murine T-Cell Orphan G-Protein-Coupled Receptor Similar to the Growth Hormone Secretagogue and Neurotensin Receptors", Genomics, (1998), pp. 223-229, Vol. 52.	
	A16	K. K. McKEE, et al., "Cloning and Characterization of Two Human G Protein-Coupled Receptor Genes (GPR38 and GPR39) Related to the Growth Hormone Secretagogue and Neurotensin Receptors", Genomics, (1997), pp. 426-434, Vol. 46.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.